155 related articles for article (PubMed ID: 11368807)
1. Impact of short-term adherence on virological and immunological success of HAART: a case study among French HIV-infected IDUs.
Pradier C; Carrieri P; Bentz L; Spire B; Dellamonica P; Moreau J; Moatti JP
Int J STD AIDS; 2001 May; 12(5):324-8. PubMed ID: 11368807
[TBL] [Abstract][Full Text] [Related]
2. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
3. Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: a nationwide population-based cohort study.
Larsen MV; Omland LH; Gerstoft J; Røge BT; Larsen CS; Pedersen G; Obel N; Kronborg G
Scand J Infect Dis; 2010 Dec; 42(11-12):917-23. PubMed ID: 20840000
[TBL] [Abstract][Full Text] [Related]
4. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
[TBL] [Abstract][Full Text] [Related]
5. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.
Wood E; Montaner JS; Yip B; Tyndall MW; Schechter MT; O'Shaughnessy MV; Hogg RS
CMAJ; 2003 Sep; 169(7):656-61. PubMed ID: 14517122
[TBL] [Abstract][Full Text] [Related]
6. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.
Kerr T; Palepu A; Barness G; Walsh J; Hogg R; Montaner J; Tyndall M; Wood E
Antivir Ther; 2004 Jun; 9(3):407-14. PubMed ID: 15259903
[TBL] [Abstract][Full Text] [Related]
7. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.
Rodríguez-Arenas MA; Jarrín I; del Amo J; Iribarren JA; Moreno S; Viciana P; Peña A; Sirvent JL; Vidal F; Lacruz J; Gutierrez F; Oteo JA; Asencio R; Castilla J; Hoyos SP;
AIDS Res Hum Retroviruses; 2006 Aug; 22(8):715-23. PubMed ID: 16910826
[TBL] [Abstract][Full Text] [Related]
8. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment.
Roux P; Carrieri MP; Cohen J; Ravaux I; Poizot-Martin I; Dellamonica P; Spire B
Clin Infect Dis; 2009 Nov; 49(9):1433-40. PubMed ID: 19807275
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcome of HAART-treated patients in a resource-limited setting: the Belgrade Cohort Study.
Jevtović D; Dragovic G; Salemović D; Ranin J; Kušić J; Marinković J; Djurković-Djaković O
Biomed Pharmacother; 2014 Apr; 68(3):391-5. PubMed ID: 24486106
[TBL] [Abstract][Full Text] [Related]
10. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
[TBL] [Abstract][Full Text] [Related]
11. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
12. Impact of pre-therapy viral load on virological response to modern first-line HAART.
Santoro MM; Armenia D; Alteri C; Flandre P; Calcagno A; Santoro M; Gori C; Fabeni L; Bellagamba R; Borghi V; Forbici F; Latini A; Palamara G; Libertone R; Tozzi V; Boumis E; Tommasi C; Pinnetti C; Ammassari A; Nicastri E; Buonomini A; Svicher V; Andreoni M; Narciso P; Mussini C; Antinori A; Ceccherini-Silberstein F; Di Perri G; Perno CF
Antivir Ther; 2013; 18(7):867-76. PubMed ID: 23343501
[TBL] [Abstract][Full Text] [Related]
13. Predictors of short-term success of antiretroviral therapy in HIV infection.
Oette M; Kroidl A; Göbels K; Stabbert A; Menge M; Sagir A; Kuschak D; O'hanley T; Bode JG; Häussinger D
J Antimicrob Chemother; 2006 Jul; 58(1):147-53. PubMed ID: 16687458
[TBL] [Abstract][Full Text] [Related]
14. Immunological and Virological Responses to Highly Active Antiretroviral Therapy in HIV-1 Infected Children.
Singh R; Mukherjee A; Singla M; Das BK; Kabra SK; Lodha R
Indian J Pediatr; 2017 Dec; 84(12):893-896. PubMed ID: 28875475
[TBL] [Abstract][Full Text] [Related]
15. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with therapeutic success in HIV-positive individuals in southern Brazil.
Silveira MP; Maurer P; Guttier MC; Moreira LB
J Clin Pharm Ther; 2015 Apr; 40(2):192-5. PubMed ID: 25422132
[TBL] [Abstract][Full Text] [Related]
17. Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens.
Horberg M; Silverberg M; Hurley L; Delorenze G; Quesenberry C
AIDS Patient Care STDS; 2008 Apr; 22(4):301-12. PubMed ID: 18338961
[TBL] [Abstract][Full Text] [Related]
18. Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more.
Nogueras M; Navarro G; Antón E; Sala M; Cervantes M; Amengual M; Segura F
BMC Infect Dis; 2006 Nov; 6():159. PubMed ID: 17087819
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA).
Cingolani A; Antinori A; Rizzo MG; Murri R; Ammassari A; Baldini F; Di Giambenedetto S; Cauda R; De Luca A
AIDS; 2002 Feb; 16(3):369-79. PubMed ID: 11834948
[TBL] [Abstract][Full Text] [Related]
20. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.
Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
AIDS; 2006 May; 20(8):1117-23. PubMed ID: 16691062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]